ImmuCell Corporation — Q1 2013 Form 10-Q
Reporting period: Three months ended March 31, 2013; filed May 14, 2013. ImmuCell develops, manufactures, and sells animal-health products for dairy and beef industries. Its lead commercial product is First Defense; Mast Out, a proposed treatment for subclinical mastitis, remains in development.
Financial performance and position
| Metric | Q1 2013 | Q1 2012 / comparison |
|---|---|---|
| Product sales | $1.847 million | $1.717 million; up about 8% |
| Gross profit / margin | $1.054 million / 57% | $1.013 million / 59% |
| Operating income | $327,000 | $281,000; up about 16% |
| Net income | $204,000; $0.07 per basic and diluted share | $155,000; $0.05 per share |
| Operating cash flow | $445,000 | $192,000 |
- Cash, cash equivalents, and short-term investments totaled $5.305 million at March 31, up $392,000 from year-end 2012. Cash alone declined to $2.320 million as short-term investments increased to $2.985 million.
- Working capital was approximately $7.082 million. Current assets were $7.667 million and current liabilities $585,000.
- Outstanding bank debt was $1.223 million, including $184,000 current and $1.040 million long-term. The unused $500,000 line of credit was available through May 31, 2014. Debt is secured by substantially all assets; the company reported compliance with covenants and a minimum $1 million liquidity covenant.
- Capital expenditures were $9,000; debt principal repayments were $45,000. Total assets were $11.111 million and stockholders’ equity was $9.413 million.
Material changes and operating drivers
- Sales growth was driven principally by First Defense: its sales increased 6% year over year. Domestic sales rose about 11%, while international sales declined 7%, partly due to distributor order timing. Two distributors accounted for 53% of quarterly sales; the largest represented 38%.
- Gross profit increased 4%, but gross margin declined two percentage points to 57%. Management cited variable biological yields, raw-material costs, and product mix as factors affecting margins; its stated objective is to keep full-year margin above 50%.
- Product development expense rose modestly to $266,000. Administrative expense decreased 1% and sales and marketing expense decreased 8% to $221,000.
- Other income/expense swung to $44,000 of net income from $11,000 of net expense. The principal reported driver was $61,000 in “Other” income, versus $72 of expense in the prior-year quarter; the filing text does not clearly explain the nature of this item. Interest expense was $17,000.
- Income tax expense was $166,000; cash income taxes paid were zero during the quarter. The cash-flow statement reports $166,000 of deferred income taxes.
Outlook, development, and risks
- Management expected 2013 financial results to be near breakeven, citing anticipated higher product-development spending than in 2012. It identified product gross margin and net operating income as key measures to monitor.
- Mast Out still required completion of FDA review and a viable manufacturing plan for its active pharmaceutical ingredient. The company expected the FDA’s Human Food Safety section completion letter in the second half of 2013. It had withdrawn its initial Chemistry, Manufacturing and Controls submission and planned a revised submission; timing depends on facility and manufacturing decisions, validation batches, and FDA review.
- Estimated investment for an API facility was $11–13 million, whether leasing and modifying an existing facility or otherwise pursuing the contemplated facility plan. No facility work had begun absent funding. The company was considering cash, debt, equity, a partner, and possible incentives, and was seeking a partner; financing and regulatory approval were not assured. Management estimated facility modifications and equipment installation could take about 18 months to two years.
- The FDA inspected the company’s facilities in Q1; management described the report as favorable and said it was responding to a few minor observations. Up to approximately $148,000 remained authorized for capital expenditures as of April 1.
- Key risks include dependence on First Defense sales; customer and receivable concentration; dairy and beef sector economics, including feed costs and weather; competition; product-development and FDA approval uncertainty; funding and manufacturing execution for Mast Out; and potential production, regulatory, and market risks. The company reported no legal proceedings and no material change in internal controls.
Important facts for investors to verify
- Whether First Defense sales growth and gross margins remain sufficient to support profitability, particularly given the lower Q1 margin.
- The source and recurrence of the $61,000 “Other” income item that materially affected Q1 non-operating results.
- Progress toward Mast Out FDA section completions, the revised manufacturing submission, and a funded, executable API production strategy.
- Availability and terms of funding for the estimated $11–13 million API facility investment, and the effect on liquidity, dilution, and debt covenants.
- Exposure to major distributors: two customers represented 53% of Q1 sales and 50% of trade receivables at March 31 (38% and 15% of sales; 32% and 18% of receivables, respectively).